In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on BioCryst (BCRX), with a price target of $13. The company’s shares closed yesterday at $7.77, close to its 52-week high of $8.13.
Fein said:
“Valuation and risks to achievement of price target. Our price target of $13 is based on the following risk-adjusted sum-of parts NPV-DCF: $10.2 for oral HAE prophylactic treatment + $1.1 for oral liquid HAE acute treatment + $0.3 for peramivir + $1.5 in cash. We assume a discount rate of 13.5%. Risks to our investment thesis and target price include: (1) failure of oral HAE agents in clinical trials; (2) failure to secure regulatory approval; and (3) a smaller than anticipated commercial opportunity, due to prophylaxis market size or degree of long-term expansion, competition, or pricing.”
According to TipRanks.com, Fein is a 5-star analyst with an average return of 12.5% and a 45.3% success rate. Fein covers the Healthcare sector, focusing on stocks such as Proteostasis Therapeutics Inc, ACADIA Pharmaceuticals Inc, and Strongbridge Biopharma Plc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for BioCryst with a $10.17 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $8.13 and a one-year low of $4.25. Currently, BioCryst has an average volume of 586.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The firm focusses on oral treatments for rare diseases. Its portfolio includes Rapivab, Kallikrein inhibitors, and BCX4430. These drugs intend to treat influenza and hereditary angioedema.
